Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Camptothecin | HCID 24360 | — |
| Reactant | Metaperiodic acid | HCID 65185 | — |
| Reactant | tert-Butyl bromoacetate | HCID 79177 | — |
| Reactant | Trifluoroacetate | HCID 84468 | — |
| Reactant | Sodium borohydride | HCID 4311764 | — |
| Catalyst | Zinc | HCID 23994 | — |
| Product | Homocamptothecin | HCID 10666346 | — |
Reaction Steps
is prepared according to the procedure of Bigg et al. (Bioorg. Med. Chem. Lett. 1997, 17, 2235-2238) by the reduction of camptothecin with sodium borohydride. This furnishes the hydroxylactol which converts to formyloxy-mappicin ketone using periodic acid. The reaction of this ketone with zinc and t-butyl bromoacetate followed treatment with trifluoroacetate affords homocamptothecin. To then derivitize homocamptothecin at the 12-position, a suspension of homocamptothecin (3.12 g, 8.6 mmol) in a mixture of chloroacetaldehyde (18 ml) and H2O (75 ml) is prepared. 75% H2SO4 (75 ml) is added dropwise, and then FeSO47H2O (2.40 g, 8.6 mmol) was added. To the ice-cold mixture, 30% H2O2 (15 ml, 6.6 mmol) is added dropwise for 2 h with stirring. The mixture is stirred at room temperature for 14 h and then diluted with H2O, extracted with chloroform (3×200 ml), and the organic layer washed with brine and dried over MgSO4. Evaporation of the solvent renders a brown oil which upon purification using column chromatography (eluent: chloroform: methanol 98:2) yields the yellow solid product.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US06291676B1 |
|---|
| Source dataset | uspto-grants-2001_09 |
|---|
| ORD ID | ord-21251accc37a4911955cead18c50061b |
|---|
| Source note | uspto-grants-2001_09 |
|---|